🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Taiwan / NCT03812016
Recruiting Not applicable

A Feedback-enabled Magnetic Device for Temporary Management of Blepharoptosis

NCT03812016 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2023-04-01
Last updated
2026-09-23

Condition(s) studied

BlepharoptosisDevice Usability

Investigational drug(s) / intervention(s)

Feedback-enabled magnetic device

Feedback-enabled magnetic device: The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode and one sensor, a magnetic actuator, an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the feedback-enabled magnetic device.

Study summary

To develop a feedback-enabled magnetic device for management of blepharoptosis and evaluate its efficacy and safety, including the gain of palpebral fissure height, visual field obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid, by performing a human trial on patients with blepharoptosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with ptosis; they are capable of understanding and complying with protocol requirements * Aged 18 years old or older Exclusion Criteria: * Upper eyelid scar, contracture, or fibrosis due to previous surgical intervention(s) * Patients with psychiatric (or mental) disorders; they are unable to cooperate or follow the study procedure * Children younger than 18 years of age

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
E-Da Hospital Kaohsiung City Taiwan Recruiting
Shin Kong Wu Ho-Su Memorial Hospital Taipei Taiwan Recruiting

More E-DA Hospital trials in Taiwan

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03812016 on ClinicalTrials.gov ↗ ← All trials in Taiwan